Omeros (NASDAQ:OMER) Upgraded by Wall Street Zen to Hold Rating

Omeros (NASDAQ:OMER) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

OMER has been the subject of several other research reports. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Finally, HC Wainwright boosted their price target on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Stock Performance

Shares of NASDAQ OMER opened at $10.90 on Friday. The stock’s 50-day simple moving average is $11.36 and its 200-day simple moving average is $9.83. The firm has a market capitalization of $784.80 million, a PE ratio of -21.80 and a beta of 2.53. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $3.69. On average, sell-side analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Omeros news, CAO David J. Borges sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently modified their holdings of OMER. Vanguard Group Inc. raised its position in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares during the last quarter. UBS Group AG boosted its stake in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the period. Geode Capital Management LLC grew its position in Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after purchasing an additional 95,979 shares during the last quarter. State Street Corp grew its position in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after purchasing an additional 263,095 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

More Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros says it has reached a profitability milestone as part of a strategic shift toward commercialization and partnerships, which management says should improve cash flow and de-risk the business. Omeros Reaches Profitability Milestone Amid Strategic Shift
• Positive Sentiment: HC Wainwright raised near-term EPS estimates for multiple 2026 quarters and lifted FY2026/FY2027 forecasts, while keeping a Buy rating and a $40 price target — a bullish analyst stance that supports higher share valuations. HC Wainwright raises estimates and reiterates Buy, $40 PT
• Positive Sentiment: Q4 results were stronger than expected (company-reported EPS beat and a licensing/deal with Novo Nordisk cited as boosting Q4), providing immediate revenue/earnings proof points that likely pushed the stock higher. Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Unusually large call-option purchases were reported, signaling bullish positioning by traders and adding short-term upside pressure. Traders Purchase Large Volume of Call Options on Omeros
• Neutral Sentiment: Several analyst and market-commentary pieces outline the bull case ahead of Q1 commercial updates and provide earnings-call detail — useful for context but not immediate catalysts on their own. Omeros: Making The Bull Case On Q4 Earnings
• Neutral Sentiment: Earnings call transcript and summaries are available for deeper detail on guidance and commercialization plans; these will matter when management discusses Q1 commercial progress. Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed several longer-term EPS estimates (FY2028–FY2030), lowering some multi-year upside expectations — a signal that while near-term outlook improved, longer-term model risk remains. HC Wainwright trims long-term EPS forecasts

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.